April Ferguson, MD
Infectious Disease · Olympia, WANPI 1811167588
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.6% of the total across 396 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,716 and has fallen 91.9% since, to $139 in 2025.
Across 396 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$1K
- Paratek Pharmaceuticals, Inc.$1K
- Gilead$1K
- Merck$743
- Insmed, Inc.$524
- Johnson & Johnson$432
- plus $2K from 21 others
What the payments were for
- Speaking & faculty fees$941%
- Food & beverage$7,42099%
- Education$110%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 68 | $1,367 |
| Paratek Pharmaceuticals, Inc. | 59 | $1,094 |
| Gilead | 55 | $1,037 |
| Merck | 42 | $743 |
| Insmed, Inc. | 27 | $524 |
| Johnson & Johnson(2 entities) | 26 | $432 |
| Theratechnologies Inc. | 15 | $380 |
| Astellas Pharma US Inc | 15 | $306 |
| Melinta Therapeutics, LLC | 16 | $302 |
| Shionogi Inc | 14 | $244 |
| AbbVie(2 entities) | 11 | $186 |
| Napo Pharmaceuticals Inc | 9 | $162 |
| Amarin Pharma, Inc. | 8 | $156 |
| EMD Serono, Inc. | 6 | $126 |
| Mayne Pharma Commercial LLC | 4 | $120 |
| Nabriva Therapeutics, PLC | 5 | $64 |
| Pfizer | 3 | $55 |
| La Jolla Pharmaceutical Company | 3 | $49 |
| Smith+Nephew | 2 | $49 |
| Vyera Pharmaceuticals, LLC | 1 | $25 |
| Kowa Pharmaceuticals America, Inc. | 1 | $20 |
| Nestle Healthcare Nutrition Inc. | 1 | $20 |
| Philips North America LLC | 1 | $15 |
| Ferring Pharmaceuticals Inc. | 1 | $14 |
| Tetraphase Pharmaceuticals, Inc. | 1 | $13 |
| Baxter Healthcare | 1 | $12 |
| Kerecis Limited | 1 | $10 |
How this compares
$7,525 in reported general payments places this provider in the 85th percentile of 186 infectious disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 56 | $232,540 |
| DovatoDolutegravir Sodium/Lamivudine | 55 | $195,919 |
| SymtuzaDarunavir/Cob/Emtri/Tenof Alaf | 31 | $145,009 |
| JulucaDolutegravir/Rilpivirine | 21 | $70,603 |
| TivicayDolutegravir Sodium | 13 | $29,503 |
| ColistimethateColistin (Colistimethate Na) | 11 | $18,737 |
| Daptomycin | 47 | $13,309 |
| Tigecycline | 13 | $8,979 |
| Bicillin L-APenicillin G Benzathine | 12 | $7,578 |
| ErtapenemErtapenem Sodium | 27 | $5,327 |
| Piperacillin-TazobactamPiperacillin Sodium/Tazobactam | 31 | $5,199 |
| Nafcillin Sodium | 14 | $4,966 |
| Meropenem | 21 | $3,928 |
| Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod | 26 | $3,924 |
| Rifampin | 21 | $2,711 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Viiv Healthcare CompanyDovato, Juluca, Tivicay | $1,367 | $296,02589 claims |
| GileadBiktarvy | $1,037 | $232,54056 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 186 infectious disease providers in Washington.
Other infectious disease in Olympia
- Francis RiedoKirkland$183K
- Warren DingesSeattle$173K
- Paul DrainSeattle$149K
- Corey CasperSeattle$115K
- Anna WaldSeattle$103K
- Jim BoonyaratanakornkitSeattle$62K
- Michael BoeckhSeattle$59K
- Jason GoldmanSeattle$58K
- Connie CelumSeattle$57K
- Hyang KimSeattle$51K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.